Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel zoonotic virus
identified as the cause of coronavirus disease 2019 (COVID-19) that has crossed species …

Since the rapidly evolving outbreak of COVID-19, several empirical therapeutic options have
been recommended including the use of antivirals, steroids, and vaccines. According to …

Background The aim of this randomized, controlled trial is to determine whether antisevere
acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against …

The pathogenesis and immunopathological damage of severe forms of COVID-19 resemble
acute autoimmune disease sparked by SARS-CoV-2, including an early systemic …

Background Intravenous immunoglobulin (IVIG) is usually used as supportive therapy, but
the treatment of COVID-19 by IVIG is controversial. This rapid review aims to explore the …

Background Interventions mitigating progression to mechanical ventilation in COVID-19
would markedly improve outcome and reduce healthcare utilization. We hypothesized that …

Background A profound inflammation-mediated lung injury with long-term acute respiratory
distress and high mortality is one of the major complications of critical COVID-19 …

Introduction In patients with common variable immunodeficiency (CVID), immunological
response is compromised. Knowledge about COVID‐19 in CVID patients is sparse. We …

Background: This study assesses the feasibility of producing hyperimmune anti-COVID-19
intravenously administrable immunoglobulin (C-IVIG) from pooled convalescent plasma …

Background The proportion of critically ill COVID-19 patients has collapsed hospital care
worldwide. The need for alternative therapies for this group of patients is imperative. This …